Dermal Mycosis Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Dermal Mycosis Epidemiology Forecast Report Coverage

Expert Market Research's “Dermal Mycosis Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of dermal mycosis. It projects the future incidence and prevalence rates of dermal mycosis cases across various populations. The study covers age, gender, and type as major determinants of the dermal mycosis population. The report highlights patterns in the prevalence of dermal mycosis over time and projects future trends based on multiple variables.

Dermal Mycosis Understanding: Disease Overview

Dermal mycosis refers to superficial fungal infections affecting the skin, hair, and nails, most commonly caused by dermatophytes, Candida species, and Malassezia. These infections thrive in warm, humid environments and are highly prevalent worldwide. Clinical manifestations vary by anatomical site and pathogen, ranging from localized erythematous, scaly plaques to chronic nail dystrophy. Although generally non-life-threatening, dermal mycoses contribute substantially to morbidity, recurrence, and healthcare utilization. Rising antifungal resistance, inappropriate steroid use, and increasing metabolic comorbidities have contributed to more persistent and treatment-refractory presentations in recent years.

Dermal Mycosis Epidemiology Perspective

The dermal mycosis epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the dermal mycosis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for dermal mycosis and their trends. The dermal mycosis detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• In 2021, dermal mycoses, including dermatophytosis, pityriasis versicolor, and cutaneous candidiasis, had a global prevalence of 616.5 million cases and 1,729.2 million new annual cases across all ages.
• Globally, males exhibit a slightly higher burden of dermal mycoses than females, reflecting modest sex-based differences in incidence, prevalence, and outpatient dermatology consultations for fungal skin diseases.
• Age distribution analysis shows that children aged 5-9 years have the highest prevalence and incidence of dermal mycoses globally, highlighting school-age exposure and transmission as major contributing factors.
• Black and Hispanic populations exhibit higher diagnosed rates of tinea versicolor, with Black individuals showing approximately 1.38‑fold and Hispanic individuals 1.26‑fold increased odds compared to White individuals, highlighting notable ethnic disparities in dermal mycosis prevalence.

Read more about this report - Request a Free Sample

Country-wise Dermal Mycosis Epidemiology Segment

The dermal mycosis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Dermal mycoses exert a notable clinical burden across diverse regions. In India, superficial fungal infections such as dermatophytosis have shown prevalence estimates ranging from about 6.1% to 27.6% in southern hospital settings and up to 61.5% in northern hospital‑based studies, with rising chronic and recurrent cases reported. In Japan’s 2021 epidemiological survey, 9,442 patients were diagnosed with dermatomycoses, overwhelmingly dermatophytosis (86.3%), followed by candidiasis (8.4%) and Malassezia infections (5.1%). These findings highlight ongoing challenges requiring strengthened dermatological surveillance and management.

Dermal Mycosis: Treatment Overview

Management of dermal mycosis depends on infection severity, site, and causative organism. Topical antifungals such as azoles and allylamines remain first-line therapy for localized infections. Oral agents, including terbinafine, itraconazole, or fluconazole, are recommended for extensive, chronic, or nail involvement. Treatment duration varies from weeks to several months, particularly for onychomycosis. Adjunctive measures include hygiene optimization, moisture control, and avoidance of topical steroid misuse. Increasing antifungal resistance has necessitated culture-guided therapy in refractory cases, emphasizing the importance of appropriate drug selection and adherence to prevent recurrence.

Key Questions Answered

• What are the key findings of dermal mycosis epidemiology in the 8 major markets?
• What will be the total number of patients with dermal mycosis across the 8 major markets during the forecast period?
• What was the country-wise dermal mycosis epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of dermal mycosis during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of dermal mycosis during the forecast period of 2026-2035?
• What are the currently available treatments for dermal mycosis?
• What are the disease risks, signs, symptoms, and unmet needs of dermal mycosis?

Scope of the Dermal Mycosis Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of dermal mycosis based on several factors.
• Dermal Mycosis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The dermal mycosis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Onychomycosis Market Size

Onychomycosis Pipeline Analysis